Moderna filed for marketing authorization for its seasonal influenza vaccine, mRNA-1010. The company submitted applications to the U.S. FDA, the European Medicines Agency (EMA), Health Canada, and Australia's Therapeutic Goods Administration. The filing targets adults aged 50 and older.
This move represents a major step in expanding Moderna's product offerings beyond its COVID-19 vaccine.
CEO Stéphane Bancel highlighted the potential of mRNA technology to more closely match evolving flu strains and address public health challenges.
Moderna views the potential approval and launch of this vaccine as a key opportunity to support its continued growth in 2027 and beyond.